A phase II study of cisplatin in patients with biliary tract carcinoma.
A phase II study of cisplatin was performed in 13 previously untreated patients with unresectable biliary tract carcinoma. The drug was given intravenously at a dose of 80 mg/m2/day once every 4 weeks. Of 13 patients evaluated, 1 showed partial response lasting 3 months, while no patients showed complete response. Of 9 patients, whose serum level of carcinoembryonic antigen (CEA) was high (> or = 10 ng/ml) before treatment, 4 showed > or = 50% reduction in serum CEA level after treatment. The current study indicates that cisplatin does not have significant antitumor activity against biliary tract carcinoma.
Okada
S
S
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Ishii
H
H
Nose
H
H
Yoshimori
M
M
Okusaka
T
T
Aoki
K
K
Iwasaki
M
M
Furuse
J
J
Yoshino
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D001661:Biliary Tract Neoplasms / Q000188:drug therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D002272:Carcinoembryonic Antigen; D002945:Cisplatin